Literature DB >> 8805758

Rank invariant tests for interval censored data under the grouped continuous model.

M P Fay1.   

Abstract

This paper creates rank invariant score tests for grouped or interval censored data. This generalizes Finkelstein (1986, Biometrics 42, 845-854), who derived score tests for interval censored data assuming proportional hazards. We frame the problem as a linear rank test of a shift in location with a known error distribution. We discuss adjustments to the test that may be required when the number of observation times is large. We offer a graphical test of the assumption of the location shift model and discuss an alternative interpretation of the test using the logistic error when the location shift assumption does not hold.

Mesh:

Year:  1996        PMID: 8805758

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  5 in total

1.  Weighted logrank tests for interval censored data when assessment times depend on treatment.

Authors:  Michael P Fay; Joanna H Shih
Journal:  Stat Med       Date:  2012-07-11       Impact factor: 2.373

2.  Exact and Asymptotic Weighted Logrank Tests for Interval Censored Data: The interval R package.

Authors:  Michael P Fay; Pamela A Shaw
Journal:  J Stat Softw       Date:  2010-08       Impact factor: 6.440

3.  A score test for comparing cross-sectional survival data with a fraction of non-susceptible patients and its application in clinical immunology.

Authors:  Sarah Flora Jonas; Cyprien Mbogning; Signe Hässler; Philippe Broët
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

4.  Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients.

Authors:  Pierre-Yves Boëlle; Dominique Debray; Loic Guillot; Annick Clement; Harriet Corvol
Journal:  Hepatology       Date:  2018-12-28       Impact factor: 17.425

5.  Study protocol: efficacy of oral alitretinoin versus oral cyclosporine A in patients with severe recurrent vesicular hand eczema (ALICsA): a randomised prospective open-label trial with blinded outcome assessment.

Authors:  Jart Ate Franke Oosterhaven; Marie Louise Anna Schuttelaar
Journal:  BMJ Open       Date:  2018-07-11       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.